Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
What is Genetic Engineering?00:49

What is Genetic Engineering?

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Guidance on communication and informed consent with patients and their families for experimental individualized treatments.

American journal of human genetics·2026
Same author

Paying for precision: funding approaches for N-of-1 trials of individualized gene targeted therapies.

Orphanet journal of rare diseases·2026
Same author

Unraveling the spatial landscape of dystrophinopathies: a transcriptomic approach to Becker and Duchenne muscular dystrophies.

The Journal of pathology·2026
Same author

TREAT-NMD advisory committee for therapeutics: Preclinical and clinical learnings from 15 years of TACT.

Journal of neuromuscular diseases·2026
Same author

Myonuclear Domain-Associated and Central Nucleation-Dependent Spatial Restriction of Dystrophin Protein Expression.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Conjugated Antisense Oligonucleotides for Skipping of Duchenne Muscular Dystrophy Exon 53: A Cautionary Study.

Nucleic acid therapeutics·2026

Related Experiment Video

Updated: May 19, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

Gene therapy for Duchenne muscular dystrophy.

Ingrid E C Verhaart1, Annemieke Aartsma-Rus

  • 1Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands.

Current Opinion in Neurology
|August 16, 2012
PubMed
Summary

Gene therapy offers new hope for Duchenne muscular dystrophy, with exon skipping most advanced and gene transfer showing promise for long-term effects. These innovative treatments aim to slow disease progression in patients lacking a cure.

More Related Videos

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
09:00

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

Related Experiment Videos

Last Updated: May 19, 2026

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors
07:44

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

Published on: September 14, 2019

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice
09:00

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

Area of Science:

  • Biomedical research
  • Neuromuscular disorders
  • Gene therapy

Background:

  • Duchenne muscular dystrophy (DMD) is a severe, incurable neuromuscular disease.
  • Recent advancements in gene therapy offer potential treatment avenues for DMD.
  • This review focuses on the current status of gene therapy approaches for DMD.

Purpose of the Study:

  • To review the present status of gene therapy approaches for Duchenne muscular dystrophy.
  • To highlight recent findings from clinical trials and preclinical studies.
  • To discuss the potential and challenges of emerging DMD gene therapies.

Main Methods:

  • Review of recent publications on gene therapy clinical trials for DMD.
  • Analysis of data from systemic clinical trials and animal models.
  • Evaluation of gene transfer strategies using viral vectors and minidystrophin genes.

Main Results:

  • Exon skipping is the most clinically advanced approach, showing encouraging results in trials and improved cardiac delivery in animal models.
  • Gene transfer using viral vectors for minidystrophin delivery has shown early-stage trial results.
  • Animal studies indicate potential solutions for vector immunogenicity and systemic delivery challenges in gene therapy.

Conclusions:

  • Significant progress has been made in developing gene therapy for Duchenne muscular dystrophy.
  • Current gene therapy strategies aim to mitigate disease progression.
  • Robust outcome measures are essential for evaluating the efficacy of these novel treatments.